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Assessment of Serologic Immunity to Diphtheria-Tetanus-
Pertussis After Treatment of Korean Pediatric Hematology and 
Oncology Patients
The aim of this study was to investigate the diphtheria-tetanus-pertussis antibody titers 
after antineoplastic treatment and to suggest an appropriate vaccination approach for 
pediatric hemato-oncologic patients. A total of 146 children with either malignancy in 
remission after cessation of therapy or bone marrow failure were recruited. All children had 
received routine immunization including diphtheria-tetanus-acellular pertussis vaccination 
before diagnosis of cancer. The serologic immunity to diphtheria, tetanus and pertussis was 
classified as: completely protective, partially protective, or non-protective. Non-protective 
serum antibody titer for diphtheria, tetanus and pertussis was detected in 6.2%, 11.6%, 
and 62.3% of patients, respectively, and partial protective serum antibody titer for 
diphtheria, tetanus and pertussis was seen in 37%, 28.1%, and 8.9% of patients. There 
was no significant correlation between the severity of immune defect and age, gender or 
underlying disease. Revaccination after antineoplastic therapy showed significantly higher 
levels of antibody for each vaccine antigen. Our data indicates that a large proportion of 
children lacked protective serum concentrations of antibodies against diphtheria, tetanus, 
and pertussis. This suggests that reimmunization of these patients is necessary after 
completion of antineoplastic treatment. Also, prospective studies should be undertaken 
with the aim of devising a common strategy of revaccination.
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INTRODUCTION
Outcome and long-term survival of pediatric patients with ma-
lignancies have improved markedly, enabling children to lead  
a normal life (1). The threat of infectious diseases, however, re-
mains imminent. This increased risk is due to secondary immu-
nodeficiency caused by malignancy and its treatment, which 
may include the loss of vaccine-induced antibodies and immu-
nological memory (2-4). The resulting susceptibility to infectious 
diseases increases morbidity and mortality in pediatric hema-
tology and oncology patients. Unfortunately, it is unclear to date 
whether and to what extent the host defense against vaccine-
preventable disease after the end of treatment is effective, which, 
in turn, has an important impact on preventive strategies. Nev-
ertheless, these studies in patients with malignancies have not 
been conducted in Korea before. 
  With awareness of the emerging presence of vaccine-prevent-
able diseases in the general population in recent years, we be-
lieved it was necessary to ascertain the level of protection against 
these diseases in our patients. We focused on the assessment of 
serologic immunity against diphtheria, tetanus and pertussis to 
determine whether these patients are in danger of acquiring 
these infections when naturally exposed. We further sought to 
investigate the level to which the generally proposed catch-up 
vaccination schedules were completed in our patients after treat-
ment and determine the factors in patient history that may have 
affected serologic protection.
MATERIALS AND METHODS
Study design
We conducted a retrospective trial to assess the immunity of 
diphtheria, tetatnus and pertussis. To determine the influence 
of the antineoplastic treatment, we compared antibody status 
to the previously published data on immunocompetent Korean 
children (5). For further evaluation patients were divided accord-
ing to age, sex, underlying disease, treatment regimen, revacci-
nation history after treatment, and then the antibody levels were 
compared.Kwon HJ, et al.  •  Immunity against Diphtheria-Tetanus-Pertussis after Antineoplastic Therapy 
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Patient population
A total of 146 patients aged 1-17 yr old who had been treated suc-
cessfully for pediatric hematologic malignancies, solid tumors, 
and bone marrow failure were recruited. They had all been di-
agnosed and received treatment at the Department of Pediatrics, 
Seoul St. Mary’s hospital, which is a tertiary referral center for 
pediatric cancers in Seoul. All patients were in remission at the 
time of study. Before the primary diagnosis, all the children had 
been immunized against diphtheria, tetanus and pertussis ac-
cording to the Korean national immunization program, with at 
least three doses of DTaP vaccines within the first year of life. 
Exclusion criteria included: 1) patients who developed relapse 
of primary disease or secondary malignancies during the study 
period; 2) patients who were still receiving systemic steroid for 
their primary disease or other conditions; and 3) patients with 
a past history of those listed vaccine-preventable diseases. 
Antibody assays
Serum antibody concentrations were measured for the follow-
ing antigens: diphtheria toxoid (DT); tetanus toxoid (TT) and 
pertussis toxin (PT). Commercially available kits were used for 
the determination of antibody titers. Serum levels of specific anti-
bodies to diphtheria, tetanus and anti-PT antibody were mea-
sured by enzyme-linked immunosorbent assay (ELISA) (IBL, 
Hamburg, Germany). The thresholds for complete, partial and 
non protection were taken from national recommendations, 
literature and manufacturer’s guidelines. Levels less than 0.01 
IU/mL for anti-DT and anti-TT were interpreted as non-protec-
tive level, and levels less than 16 EU/mL for anti-PT as non-pro-
tective level. For diphtheria and tetanus, titers of 0.01 to less than 
0.1 IU/mL were considered to produce a partial protection, and 
titers 0.1 IU/mL or greater were deemed to provide complete 
protection. For pertussis, antibody levels 24 EU/mL or greater 
were considered as completely protective, and 16 to less than 
24 EU/mL as partially protective.
Statistical analysis
Antibody titers of patient groups and controls were compared 
with Student’s t-test. The methods of chi-square test and Fisher’s 
exact test were applied for comparing seropositive proportions 
between the groups. Data were analyzed using SPSS statistical 
software, version 13.0 for Windows (Chicago, IL, USA). P values 
less than 0.05 were considered statistically significant through-
out analysis. 
Ethics statement
This study protocol was approved by the institutional review 
board (IRB) of Seoul St. Mary’s Hospital (IRB approval number: 
KC10PISV0432). Patients and/or their parents gave informed 
written consent prior to study.
RESULTS
Patient characteristics
A total 146 patients were recruited in the study. The demographic 
and clinical characteristics of the patients are shown in Table 1. 
The current study included 89 males and 57 females with a me-
dian age at enrollment of 11.6 ± 3.6 yr old (range, 3-17 yr). One 
hundred thirty-seven patients (93.8%) had hematologic diseases, 
including acute lymphoblastic leukemia (ALL) in 83 patients, 
acute myeloid leukemia (AML) in 39 patients, aplastic anemia 
in 11 patients and chronic myeloid leukemia (CML) in 4 patients. 
Nine patients (6.2%) had been treated for solid tumors includ-
ing 6 for Hodgkin lymphoma, 2 for neuroblastoma, 1 for Wilms’ 
tumor. Amongst all patients, 92 patients had received chemo-
therapy alone, while 54 patients had also undergone hemato-
poietic stem cell transplantation (HSCT). Antibody titers for diph-
theria, tetanus, and pertussis were measured 3-138 months after 
the end of treatment. 
Immunity to diphtheria
Only 56.8% of the patients had completely protective levels of 
diphtheria antibody. The percentage of patients with non-pro-
tective antibody to diphtheria was 6.2%; and 37% of participants 
were partially protectective. In comparison with the previous 
published data in age-matched, healthy Korean children (Group 
B), the seroprotective rate against diphtheria in our cohort (Group 
A) was significantly lower (Fig. 1, P < 0.001).
  The percentage of seropositivity against diphtheria according 
to patient characteristics is shown in Table 2. When antibody lev-
els were examined by sex, no differences were observed. Among 
patients aged 7 yr or older, the proportion of patients with protec-
tive antibody levels remained similar to patients younger than 7 
yr of age (P = 0.084). The detected antibody levels were not sig-
Table 1. Baseline characteristics of patients included in this study
Patients characteristics No. (%) of patients
Gender
   Male
   Female
 
89 (61)
57 (39)
Age (yr)
   Mean ± SD
   Range
 
11.6 ± 3.6
3-17
Primary diagnosis
   Hematology
      ALL
      AML
      CML
      Aplastic anemia
   Solid tumor
      Lymphoma
      Neuroblastoma
      Wilms’ tumor
 
 137 (93.8)
   83 (56.8)
   39 (26.7)
   4 (2.8)
 11 (7.5)
   9 (6.2)   
   6 (4.1)
   2 (1.4)
   1 (0.7)
Antineoplastic treatment
   Chemotherapy
   HSCT
 
92 (63)
54 (37)
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chromic my-
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nificantly different according to underlying disease of the pa-
tient. Analysis of patients who had received chemotherapy only 
compared with those who had received HSCT again showed no 
significant differences. The patients who had received DTaP or 
diphtheria-tetanus (Td) vaccines after completion of therapy 
were significantly more likely than patients lacking post-treat-
ment reimmunization to have higher protective concentration 
of diphtheria antibody (P = 0.001).
Immunity to tetanus
Sixty percent of the patients had protective levels of antibody to 
tetanus. The percentage of patients with non-protective anti-
body to tetanus was 11.6%; and 28.1% of participants were par-
tially protective. A comparative analysis with the immunocom-
petent group revealed a significant decline in seropositive rate 
against tetanus in our cohort (Fig. 1). 
  As was seen with diphtheria antibody, protective levels of anti-
body to tetanus did not differ according to sex and age. Under-
lying disease did not significantly influence antibody levels. There 
were no significant differences between patients treated with 
chemotherapy alone and those treated by HSCT with regards 
to antibody levels to tetanus. On comparing the reimmunization 
group with the non-reimmunization group after treatment, we 
found a significantly higher number of patients presenting with 
complete protection to tetanus in the reimmunization group 
(P < 0.001). Among patients in the reimmunization group, the 
proportion of those with protective levels of antibody remained 
stable at approximately 80% (Table 2). 
Immunity to pertussis
Only twenty-eight percent of the patients had protective levels 
of anti-PT antibody to pertussis. The percentage of patients with 
non-protective antibody to pertussis was 62.3%; and 8.9% of 
participants were partially protectective. The previous data for 
healthy children revealed that the seroprotection rate against 
pertussis accounted for 72.4%, whereas the percentage of pro-
tective levels significantly dropped to 28.8% in our patients (Fig. 
1, P < 0.001).
  There was no statistically significant difference in antibody 
levels with respect to sex and age. The seropositivity of pertussis 
also did not differ according to underlying disease. The patients 
who completed chemotherapy only had a lower protective an-
tibody levels than HSCT patients had (P = 0.039).
  The disparity in levels of protective antibody between the re-
immunization group and non-reimmunization group that had 
been evident for diphtheria and tetanus was not shown for per-
tussis. The proportion of patients in recipients of DTaP or Td af-
ter completion of therapy with protective levels of antibody to 
pertussis was not different from the patients in non-reimmuni-
zation group (Table 2).
DISCUSSION
Although survival of children with malignancies has improved, 
both aggressive antineoplastic treatment and the underlying dis-
Table 2. Seroprotection rates against diphtheria, tetanus and pertussis according to patient factors
Group
Diphtheria Tetanus Pertussis
Percentage (%) P value Percentage (%) P value Percentage (%) P value
Sex
   Female (n = 57)
   Male (n = 89)
 
49.1
60.7
 
0.308
 
45.6
69.7
 
0.704
 
31.6
28.1
 
0.137
Age
   < 7 yr (n = 18)
   ≥ 7 yr (n = 128)
 
61.1
56.2
 
0.084
 
44.5
62.5
 
0.220
 
11.1
31.3
 
0.140
Underlying disease
   Hematology (n = 137)
   Solid tumors (n = 6)
 
56.2
66.7
 
0.232
 
59.9
66.7
 
1.000
 
23.2
22.2
 
1.000
Treatment
   Chemotherapy (n = 92)
   HSCT (n = 54)
 
51.1
66.7
 
0.067
 
55.4
68.5
 
0.119
 
22.8
38.9
 
0.039
Reimmunization after treatment
   No (n = 87)
   Yes (n = 59)
 
46.0
72.9
 
0.001
 
47.1
79.7
 
< 0.001
 
21.8
39.0
 
0.176
	 Diphtheria	 Tetanus	 Pertussis
56.8%
88.3%
P	<	0.001
60.3%
85.2%
P	<	0.001
28.8%
72.4%
P	<	0.001
Group	A
Group	B
Fig. 1. Comparison of seroprotection rates against diphtheria, tetanus, and pertussis 
between group A (our cohort) and group B (healthy children in previous data).Kwon HJ, et al.  •  Immunity against Diphtheria-Tetanus-Pertussis after Antineoplastic Therapy 
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ease may result in secondary immunodeficiency (6, 7). Owing 
to the reconstituting immune system, these patients are at risk 
of acquiring a variety of infectious diseases (8, 9). The recent out-
breaks of vaccine preventable disease as well as the increase of 
pertussis in immunocompetent individuals further address the 
need for protective strategy in children with hemato-oncologic 
illnesses (10-15). We therefore assessed the serologic immunity 
against diphtheria, tetanus and pertussis antigens in a total of 
146 children treated for malignancy. In a previous study that we 
performed at St. Mary’s hospital and published in 2008, we have 
demonstrated the seroprotective rate of diphtheria, tetanus and 
pertussis in healthy Korean children (5). In this study, we com-
pared the antibody levels in our patient group to those of a healthy 
historical cohort in order to assess the immunity created by pre-
vious vaccinations after therapy. Notably, in the majority of pa-
tients these antibody levels were below the presumed threshold 
of protection for each antigen. Compared with previous data from 
age-matched normal populations in Korea who had been im-
munized according to the same schedule, rates of completely 
protective immunity in our cohort were decreased by 31.5% for 
diphtheria, 24.9% for tetanus and 43.6% for pertussis, respective-
ly. These data suggest that pediatric patients who had under-
gone treatment for cancer are highly susceptible to these infec-
tions when naturally exposed. Our findings are consistent with 
other published data. In the report by van der Hardt et al. (16), 
more than 50% of patients lacked protective immunity against 
diphtheria and tetanus after antineoplastic therapy. Ek et al. (17) 
found that only 17% of ALL patients had complete protection 
against diphtheria and 33% against tetanus after treatment. Small 
et al. (18) reported that more than 30% of autologous peripheral 
blood stem cell transplantation recipients lacked pertussis im-
munity. 
  We further tried to determine factors influencing the low sero-
logic immunity of our patients. Some studies have demonstrated 
that young age is associated with more profound immune ab-
normalities, including loss of antibodies to vaccine antigens (19-
21). In our study, however, age did not have any effect on sero-
logic immunity to each antigen. Patient gender and the type of 
malignancy also did not appear to influence immunity to the 
vaccine antigens studied. 
  This study also emphasizes comparisons of immunity between 
the chemotherapy group and the HSCT group. It is worth not-
ing that immunity to diphtheria and tetanus in patients who had 
completed chemotherapy only showed no significant differences 
when compared to that of HSCT recipients. In addition, pertus-
sis immunity decreased significantly more in the chemotherapy 
group than in the HSCT group. This latter finding may be attrib-
utable to widespread use of reimmunization after HSCT. There 
are well-established recommendations for reimmunizations 
after HSCT, but no consensus still exists regarding whether re-
immunizations are necessary after standard chemotherapy, and 
when such reimmunizations should take place (22, 23). A few 
cohort studies were published to address changes of antibody 
titers and response to booster vaccine after chemotherapy (24-
26). On the basis of our data, we agree with the strategy of reim-
munizing each patient who completed chemotherapy only, as 
well as HSCT recipients. Underestimation of the need for reim-
munization may contribute to the spread of vaccine preventable 
diseases such as pertussis in society. Important questions that 
remain unanswered include the best strategy for managing chil-
dren who have completed chemotherapy. Zignol et al. who stud-
ied humoral immunity against tetanus, measles, polio, hepatitis 
B, mumps, rubella in pediatric cancer patients recommended a 
booster dose 12 months after completion of chemotherapy (19). 
Patel et al. suggested a simple schedule of one booster dose at 6 
months after completion of leukemia therapy (25). The propos-
al by Fioredda et al. was to continue the regular vaccination 
schedule according to age (27). Efforts to find a common strat-
egy should form the core of future studies.
  On comparing the reimmunization group and the non-reim-
munization group after treatment, the proportion of patients 
with protective immunity remained significantly higher in the 
reimmunization group both for diphtheria (72.9%) and for teta-
nus (79.7%). However, this difference was not observed for per-
tussis antibody. This finding reflects the high level of coverage 
made possible by reimmunization and the requirement that a 
booster dose of vaccine be given after completion of treatment. 
Although some of patients were administered reimmunization 
using DTaP according to age, this finding also suggests that cov-
erage with only Td can be incomplete with regards to pertussis. 
There are few studies on pertussis immunity following antineo-
plastic therapy and on the immunogenicity of Tdap in such pa-
tients; one study showed that HSCT recipients have lower levels 
of pertussis antibody and an inadequate response of Tdap vac-
cination (18). Ongoing prospective study will assist in answer-
ing whether observed differences in pertussis immunity can be 
affected by reimmunization using the newly approved Tdap. 
  Some limitations of our study must be considered. First, our 
study has a cross-sectional design, which does not allow us to 
draw causal relationships. The weak seropositivity in the chemo-
therapy only group may also be attributable to other factors, in-
cluding the interval between cessation of treatment and anti-
body assessment, as is suggested for children who received trans-
plants. We did not have information about antibody levels be-
fore treatment to strongly support the idea that the low seropos-
itivity to various vaccine antigens was due only to immunosup-
pressive effect of therapy. Second, we did not universally test for 
hypogammaglobulinemia, which may have affected responses. 
Third, chemotherapy was not classified according to intensity 
of regimen, a variable which has a significant effect on immune 
reconstitution. These limitations need to be addressed in future 
studies.Kwon HJ, et al.  •  Immunity against Diphtheria-Tetanus-Pertussis after Antineoplastic Therapy 
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  In summary, we have shown that a substantial proportion of 
pediatric patients with malignancies who had completed treat-
ment did not have antibody levels that are protective against 
diphtheria, tetanus and pertussis. The current recommenda-
tions by the Korean national immunization program suggest 
reimmunization of HSCT recipients. Our findings support this 
reimmunization practice. In addition, although the principle of 
reimmunization of patients after chemotherapy for malignancy 
is not universally accepted, these patients also lacked protective 
serum levels in a manner similar to those who had undergone 
HSCT, especially against pertussis. Children who demonstrate 
a defective response to common pediatric vaccines should be 
evaluated, and revaccinated if indicated, to ensure that these 
children maintain protective antibody responses. For example, 
the use of Tdap by a booster vaccine may be one alternative that 
could be studied further. Future prospective studies should aim 
towards creating a consensus for modified dosing and reimmu-
nization schedules after treatment for malignancies.
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